Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 9—September 2016

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Yaseen M. ArabiComments to Author , Ali H. Hajeer, Thomas Luke, Kanakatte Raviprakash, Hanan Balkhy, Sameera Johani, Abdulaziz Al-Dawood, Saad Al-Qahtani, Awad Al-Omari, Fahad Al-Hameed, Frederick G. Hayden1, Robert Fowler, Abderrezak Bouchama, Nahoko Shindo, Khalid Al-Khairy, Gail Carson, Yusri Taha, Musharaf Sadat, and Mashail Alahmadi
Author affiliations: King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M. Arabi, A.H. Hajeer , H. Balkhy, S. Johani, A. Al-Dawood, S. Al-Qahtani, A. Bouchama, K. Al-Khairy, M. Sadat, M. Alahmadi); Naval Medical Research Center, Silver Spring, Maryland, USA (T. Luke, K. Raviprakash); Alfaisal University, Riyadh (A. Al-Omari); King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia (F. Al-Hameed); University of Virginia School of Medicine, Charlottesville, Virginia, USA (F.G. Hayden); University of Toronto, Toronto, Ontario, Canada (R. Fowler); World Health Organization, Geneva, Switzerland (N. Shindo); University of Oxford Centre for Tropical Medicine, Oxford, UK (G. Carson); King Abdulaziz Medical City, Al-Ahsa, Saudi Arabia (Y. Taha)

Main Article

Table 2

Characteristics and findings for participants with MERS-CoV antibodies detected by ELISA in a study determining the feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia*

Participant no. Age, y/sex Symptom at first medical visit Admitted to ICU MERS-CoV
rRT-PCR Days from symptom onset or exposure
to serum sampling OD ratio IFA MN titer
1 70/M ARI No 35 2.00 1:10 100
2 61/F ARI No + 10 1.12 Nonreactive 200
3 40/F ARI No 4 3.66 1:20 100
4 63/M ARI No 27 3.95 1:80 200
5 76/M ARI No + 13 2.59 1:20 200
6 73/M ARI No 4 1.62 Nonreactive Nonreactive
7 69/M ARI Yes + 87 4.70 1:1,280 400†

Healthcare worker
9 46/F ARI Yes + 24 5.51 1:40 800
10 27/M None Yes + 273 2.33 1:20 50
11 31/M ARI No + 365 1.46 1:10 Nonreactive
12 33/F None No + 365 2.34 1:10 50

*ARI, acute respiratory infection; ICU, intensive care unit; IFA, indirect immunofluorescent antibody; OD ratio, optical density value of patient sample/optical density value of calibrator; MERS-CoV, Middle East respiratory syndrome coronavirus; MN, microneutralization assay; rRT-PCR, real-time reverse transcription PCR; −, negative; +, positive.
†Serial tests were performed for the patient (Figure 2). Values shown are the highest values for the patient.

Main Article

1This author is a member of ISARIC (the International Severe Acute Respiratory and Emerging Infection Consortium).

Page created: August 16, 2016
Page updated: August 16, 2016
Page reviewed: August 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.